BioSpace News Archive

Now that most people in North America and Europe are vaccinated and the COVID-19 pandemic is diminishing, Moderna is looking for its second act.

The FDA is heading into fall with a few Prescription Drug User Fee Act (PDUFA) dates. Here’s a look at this week’s upcoming action.

BeiGene shared updates from its solid tumor development program for cornerstone PD-1 antibody tislelizumab at the European Society for Medical Oncology Congress 2022 in Paris.

Merck and Eisai announced the first presentation of results from the final analysis of the Phase 3 LEAP-002 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, versus LENVIMA monotherapy as a first-line treatment for patients with unresectable hepatocellular carcinoma.

Anaveon announces updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective interleukin-2 agonist, in poster presentations at the European Society for Medical Oncology Congress 2022, taking place in Paris, September 9 – 13, 2022.

Exelixis, Inc. announced results from the dose-escalation stage of STELLAR-001, an ongoing phase 1b trial evaluating XL092 as a single-agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors.

Immatics N.V. announced a comprehensive preclinical data set for its T cell engaging receptor product candidate IMA402 at the European Society for Medical Oncology Congress 2022 held in Paris, France, from September 9 to 13, 2022.

Elevar Therapeutics, Inc. announced top-line results from the Phase 3 study of its drug candidate rivoceranib combined with camrelizumab versus sorafenib as a first-line therapy for unresectable hepatocellular carcinoma.

Adagene Inc., a company transforming the discovery and development of novel antibody-based therapies, announced the publication of data showing the best-in-class potential of ADG126, a masked, anti-CTLA-4 SAFEbody®.

Regeneron Pharmaceuticals, Inc. announced positive early data for two novel and investigational bispecific antibodies – ubamatamab in recurrent ovarian cancer and REGN5093 in MET-altered advanced non-small cell lung cancer.